Finally, it is also worth noting that after IL-1β blockade with canakinumab in patients with ischemic heart disease, in the CANTOS trial, IL-18 remained as the main proinflammatory factor associated with increased CV risk [48]. This evidence concerns the gene IL18 and coronary artery disorder.